Laszlo Orfi

Navedeno

	Vse	Od leta 2020
Navedbe	5703	1387
indeks h	38	21
indeks i10	80	39

340

170

255

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202516 29 60 52 60 53 72 94 145 178 197 195 221 221 258 306 269 300 324 315 295 304 307 260 291 267 246 259 64

Javni dostop

Prikaži vse

32 člankov

5 člankov

na voljo

ni na voljo

Na podlagi zahtev v povezavi s financiranjem

Soavtorji

Dániel ErősPreverjeni e-poštni naslov na vichem.hu
Bálint Hegymegi-Barakonyichemist, Vichem Ltd.Preverjeni e-poštni naslov na vichem.hu
Balázs SarkadiHungarian Academy of Sciences, Semmelweis University, Institute of EnzymologyPreverjeni e-poštni naslov na biomembrane.hu
Istvan PetakSemmelweis UniversityPreverjeni e-poštni naslov na oncompassmedicine.com
RJ KokUtrecht UniversityPreverjeni e-poštni naslov na uu.nl
Alexander LevitzkiThe Hebrew UniversityPreverjeni e-poštni naslov na mail.huji.ac.il
varadi ahung* acad* sci* OR cornell OR eotvos OR res* center nat* sci*Preverjeni e-poštni naslov na enzim.hu
Stewart ColeInstitut PasteurPreverjeni e-poštni naslov na pasteur.fr
Csilla LaczkaHead of Lab at Turbine Ltd, scientific advisor at Institute of Enzymology, RCNSPreverjeni e-poštni naslov na turbine.ai
gergely szakacsInstitute of EnzymologyPreverjeni e-poštni naslov na biomembrane.hu
Klaas PoelstraProfessor of Drug Targeting, University of GroningenPreverjeni e-poštni naslov na rug.nl
Szabolcs BéniDepartment of Analytical Chemistry, Institute of Chemistry, ELTE - Eötvös Loránd UniversityPreverjeni e-poštni naslov na ttk.elte.hu
Tamas HegedusSemmelweis UniversityPreverjeni e-poštni naslov na hegelab.org
Pál GyulaváriSemmelweis University, MTA-SE Pathobiochemistry Research GroupPreverjeni e-poštni naslov na med.semmelweis-univ.hu
Cindy LariveChancellor, UC Santa CruzPreverjeni e-poštni naslov na ucsc.edu
Grietje Molemaprofessor of Life Sciences University of GroningenPreverjeni e-poštni naslov na umcg.nl
Krisztina Takács-NovákProfessor of Department of Pharmaceutical Chemistry, Semmelweis UniversityPreverjeni e-poštni naslov na pharma.semmelweis-univ.hu
Zoltán VargaBiological Nanochemistry Research Group, Institute of Materials and Environmental ChemistryPreverjeni e-poštni naslov na ttk.mta.hu
Wim HenninkProfessor, Department of Pharmaceutics, Utrecht University, The NetherlandsPreverjeni e-poštni naslov na uu.nl
Gert StormPreverjeni e-poštni naslov na uu.nl

Spremljaj

Laszlo Orfi

Department of Pharmaceutical Chemistry, Semmelweis University, Vichem Ltd.

Preverjeni e-poštni naslov na vichem.hu

Medicinal chemistry kinase signal transduction QSAR QSPR


Naslov Razvrsti po navedbah Razvrsti po letniku Razvrsti po naslovu	Navedeno Navedeno	Leto
Flk-1 as a target for tumor growth inhibition LM Strawn, G McMahon, H App, R Schreck, WR Kuchler, MP Longhi, ... Cancer Research 56 (15), 3540-3545, 1996	450	1996
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter C Özvegy-Laczka, T Hegedűs, G Várady, O Ujhelly, JD Schuetz, A Varadi, ... Molecular pharmacology 65 (6), 1485-1495, 2004	416	2004
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties C Hegedűs, C Özvegy‐Laczka, A Apati, M Magocsi, K Nemet, L Őrfi, ... British journal of pharmacology 158 (4), 1153-1164, 2009	266	2009
AXL is a potential target for therapeutic intervention in breast cancer progression YX Zhang, PG Knyazev, YV Cheburkin, K Sharma, YP Knyazev, L Orfi, ... Cancer research 68 (6), 1905-1915, 2008	265	2008
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 T Hegedűs, L Őrfi, A Seprődi, A Váradi, B Sarkadi, G Kéri Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002	253	2002
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors S Blencke, B Zech, O Engkvist, Z Greff, L Őrfi, Z Horváth, G Kéri, A Ullrich, ... Chemistry & biology 11 (5), 691-701, 2004	176	2004
Treatment of platelet derived growth factor related disorders such as cancers KP Hirth, E Mann, LK Shawyer, A Ullrich, I Szekely, T Bajor, J Haimichael, ... US Patent 6,331,555, 2001	175*	2001
Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes A Herrero, A Pinto, P Colón-Bolea, B Casar, M Jones, L Agudo-Ibáñez, ... Cancer cell 28 (2), 170-182, 2015	159	2015
Reliability of logP predictions based on calculated molecular descriptors: a critical review D Eros, I Kovesdi, L Orfi, K Takacs-Novak, G Acsády, G Kéri Current medicinal chemistry 9 (20), 1819-1829, 2002	143	2002
Acid− base profiling of imatinib (gleevec) and its fragments Z Szakács, S Béni, Z Varga, L Örfi, G Kéri, B Noszál Journal of medicinal chemistry 48 (1), 249-255, 2005	142	2005
NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling SA Barman, F Chen, Y Su, C Dimitropoulou, Y Wang, JD Catravas, W Han, ... Arteriosclerosis, thrombosis, and vascular biology 34 (8), 1704-1715, 2014	137	2014
Leads for antitubercular compounds from kinase inhibitor library screens S Magnet, RC Hartkoorn, R Székely, J Pató, JA Triccas, P Schneider, ... Tuberculosis 90 (6), 354-360, 2010	130	2010
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling K Godl, OJ Gruss, J Eickhoff, J Wissing, S Blencke, M Weber, H Degen, ... Cancer Research 65 (15), 6919-6926, 2005	124	2005
Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion J Rybniker, JM Chen, C Sala, RC Hartkoorn, A Vocat, A Benjak, ... Cell Host & Microbe 16 (4), 538-548, 2014	107	2014
Application of neural networks in structure–activity relationships I Kövesdi, MF Dominguez‐Rodriguez, L Ôrfi, G Náray‐Szabó, A Varró, ... Medicinal research reviews 19 (3), 249-269, 1999	105	1999
A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling R Székely, F Wáczek, I Szabadkai, G Németh, B Hegymegi-Barakonyi, ... Immunology letters 116 (2), 225-231, 2008	104	2008
Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors G Németh, Z Greff, A Sipos, Z Varga, R Székely, M Sebestyén, Z Jászay, ... Journal of medicinal chemistry 57 (10), 3939-3965, 2014	88	2014
Treatment of platelet derived growth factor related disorders such as cancers KP Hirth, DP Schwartz, E Mann, LK Shawver, G Keri, I Szekely, T Bajor, ... US Patent 5,700,823, 1997	88	1997
Quantitative analysis of peptides with NMR spectroscopy CK Larive, D Jayawickrama, L Orfi Applied Spectroscopy 51 (10), 1531-1536, 1997	87	1997
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer … C Hegedüs, K Truta-Feles, G Antalffy, G Várady, K Nemet, ... Biochemical pharmacology 84 (3), 260-267, 2012	85	2012

Sistem trenutno ne more izvesti postopka. Poskusite znova pozneje.

Članki 1–20

Št. navedb na leto

Podvojene navedbe

Združene navedbe

Dodajanje soavtorjevSoavtorji

Spremljaj

Navedeno

Soavtorji